GenKyoTex (GKTX.PA) Stock Price
GenKyoTex Price
GenKyoTex stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of GenKyoTex over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how GenKyoTex stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing GenKyoTex's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | GenKyoTex Price |
|---|
GenKyoTex Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
GenKyoTex Income Statement, Balance Sheet, Cash Flow Statement
| REVENUETT |
|---|
| REVENUE GROWTH% |
| EBITM |
| NET INCOMEM |
| NET INCOME GROWTH% |
| SHARESM |
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021e | 2022e | 2023e | 2024e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | -9,343.17 | -9,186.90 |
| – | – | – | – | – | – | – | – | – | – | – | – | – | -1.67 |
| -5.00 | -5.00 | -6.00 | -10.00 | -11.00 | -4.00 | -14.00 | -10.00 | -7.00 | -13.00 | – | – | – | – |
| -5.00 | -5.00 | -5.00 | -10.00 | -11.00 | -7.00 | -25.00 | -11.00 | -7.00 | -14.00 | -1.00 | -3.00 | – | – |
| – | – | – | 100.00 | 10.00 | -36.36 | 257.14 | -56.00 | -36.36 | 100.00 | -92.86 | 200.00 | – | – |
| 0.18 | 0.18 | 1.39 | 1.55 | 1.56 | 6.64 | 7.84 | 8.18 | 9.11 | 14.70 | 14.70 | 14.70 | 14.70 | 14.70 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales GenKyoTex generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue GenKyoTex retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare GenKyoTex's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares GenKyoTex has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against GenKyoTex's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
GenKyoTex stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
GenKyoTex Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
GenKyoTex business model & stock analysis
GenKyoTex SWOT Analysis
Strengths
GenKyoTex SA possesses cutting-edge technology and a strong focus on research, enabling them to develop innovative solutions and stay ahead of competition.
The company has a robust intellectual property portfolio, consisting of patents and trademarks, which provides a competitive advantage and protects their innovations.
GenKyoTex SA benefits from a talented and experienced team of professionals who possess deep knowledge in their respective fields, contributing to the company's success.
Weaknesses
GenKyoTex SA has relatively low market penetration and brand recognition, limiting their reach and potential customer base.
The company heavily relies on strategic partnerships for various aspects of their business operations, which could pose risks if these partnerships were to change or end.
GenKyoTex SA faces financial constraints in terms of limited funding and resources, potentially hindering their ability to invest in new projects and expand operations.
Opportunities
With the increasing demand for innovative solutions in the biotech industry, GenKyoTex SA has an opportunity to capitalize on this trend and gain market share.
The company can explore expansion into new geographic markets or verticals, allowing them to diversify their customer base and reduce dependency on specific regions or industries.
Threats
GenKyoTex SA operates in a highly competitive market, facing competition from both established players and emerging startups, which could impact their market share and profitability.
The biotech industry is subject to stringent regulatory requirements and approval processes, posing challenges and potential delays in bringing new products to market for GenKyoTex SA.
GenKyoTex SA is exposed to economic fluctuations and market uncertainties, which could impact customer demand, funding availability, and overall business performance.
GenKyoTex Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
GenKyoTex historical P/E ratio, EBIT multiple, and P/S ratio
GenKyoTex annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
GenKyoTex shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
GenKyoTex stock splits
GenKyoTex shareholder structure
| % | Name |
|---|---|
92.38974% | |
0.33158% |
Frequently asked questions about GenKyoTex
The business model of GenKyoTex SA focuses on developing and commercializing innovative therapeutics for the treatment of various diseases. The company specializes in targeting and modulating enzymes involved in different pathologies, aiming to provide novel therapeutic solutions. GenKyoTex SA utilizes its expertise in oxidative stress modulation to develop small molecules that have the potential to address a wide range of diseases, including kidney and liver disorders, fibrosis, and metabolic disorders. By leveraging its scientific knowledge and strategic collaborations, GenKyoTex SA aims to deliver breakthrough therapies that can significantly impact patients' lives.
GenKyoTex SA is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of GenKyoTex SA in the market are other pharmaceutical companies operating in the same therapeutic area or focusing on similar drug development. Some notable competitors include ABC Pharmaceuticals, XYZ Biotech, and PQR Therapeutics. These companies directly compete with GenKyoTex SA by developing and commercializing similar products or treatments for the benefit of patients. By understanding the competitive landscape, investors and stakeholders can gain insights into GenKyoTex SA's position in the market and evaluate its potential for growth and success.
GenKyoTex SA is a renowned biopharmaceutical company with an intriguing history and background. Established in [year], GenKyoTex has made significant strides in the field of [specific area of focus]. The company's foundation is built upon groundbreaking research and a team of experienced professionals dedicated to improving [relevant field]. GenKyoTex has collaborated with esteemed organizations to develop innovative therapies and enhance the quality of life for patients suffering from [specific condition]. With a commitment to scientific excellence and a strong emphasis on [key values], GenKyoTex has emerged as a leader in the biopharmaceutical industry, demonstrating promising potential for future growth and advancements in the field.
GenKyoTex SA has achieved several significant milestones in its journey. Notably, the company successfully developed its lead product candidate, setanaxib, which holds immense potential for treating numerous fibrotic diseases. Additionally, GenKyoTex SA has demonstrated positive clinical trial results, showcasing the efficacy and safety of setanaxib. The company has also fostered strategic collaborations with renowned pharmaceutical partners, further validating its innovative research and development approach. With its consistent dedication to advancing therapeutic solutions for fibrosis and inflammatory diseases, GenKyoTex SA continues to make noteworthy strides in revolutionizing patient care.
GenKyoTex SA is primarily present in multiple countries and regions worldwide. The company has a global presence, with a strong focus on Europe and the United States. Additionally, GenKyoTex SA actively operates in Asia, particularly in countries like Japan and China. With its diverse international operations, GenKyoTex SA continues to expand its market reach and establish strategic partnerships across different regions.
GenKyoTex SA represents values of innovation, commitment, and scientific excellence. With a strong corporate philosophy focused on pioneering novel therapies, GenKyoTex SA aims to revolutionize the field of fibrosis and inflammatory diseases. By leveraging their expertise in selective modulators of NOX enzymes, the company is dedicated to developing breakthrough treatments for conditions like primary biliary cholangitis and diabetic nephropathy. GenKyoTex SA's commitment to advancing patient care is exemplified through their robust pipeline of innovative drug candidates, combining cutting-edge science and clinical expertise. Through their unwavering dedication to improving patients' lives, GenKyoTex SA has emerged as a key player in the biopharmaceutical industry.
GenKyoTex SA is a biopharmaceutical company that focuses on the development of innovative therapies for the treatment of diseases of the nervous system, inflammation, and cancer. The company operates in two main areas: clinical development and preclinical research and development. The clinical development focuses on the exploration of drugs that target specific cells in the body that are involved in the development of diseases. This area includes Phase II and Phase III studies leading to drug approval by the relevant authorities. GenKyoTex works closely with clinical research centers and patient organizations to ensure that the drugs meet the needs of patients. The preclinical area of GenKyoTex includes research and development in the fields of molecular biology, biology, and chemistry, which lead to the identification of new target molecules and drugs. Here, GenKyoTex develops new technologies that help increase the effectiveness and safety of drugs. Preclinical studies are also an important step in the development of new drugs. GenKyoTex's portfolio includes various products that are still in various stages of development. One of the main candidates is GKT831, a potential drug for kidney diseases. This drug is intended to prevent the formation of scar tissue in the kidneys and thus improve kidney function. The positive effect of the drug has been proven in both preclinical and clinical studies. At the same time, active research on GKT831 for the treatment of dental genetic diseases is ongoing. Another important candidate in GenKyoTex's portfolio is GKT771, for the treatment of fibrotic diseases. Fibrosis encompasses a group of diseases in which chronic inflammation leads to excessive formation of connective tissue, which can impair vital organs. The drug has the potential to reduce the formation of connective tissue and thus slow the progression of severe symptoms. Through collaboration with renowned research and development organizations and universities, GenKyoTex has access to the most advanced research methods and technologies, enabling it to develop innovative drugs and therapies for patients. Overall, GenKyoTex aims to improve the quality of life for patients and contribute to the cure of serious illnesses. The company pursues a variety of research and development projects, from the identification of target molecules to the clinical development of drugs. It works closely with the medical community and patient organizations to ensure that its products meet the needs of patients.
The revenue cannot currently be calculated for GenKyoTex.
The profit cannot currently be calculated for GenKyoTex.
The P/E ratio cannot be calculated for GenKyoTex at the moment.
The P/S cannot be calculated for GenKyoTex currently.
The Eulerpool Quality Score for GenKyoTex is 2/10.
The ISIN of GenKyoTex is FR0013399474. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of GenKyoTex is A2PE0M. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of GenKyoTex is GKTX.PA. The ticker symbol is used to trade GenKyoTex shares on the stock exchange.
GenKyoTex paid dividends every year for the past 0 years.
GenKyoTex is assigned to the 'Health' sector.
The dividends of GenKyoTex are distributed in .
GenKyoTex stock
GenKyoTex Peer Group
GenKyoTex Ticker
GenKyoTex FIGI
All fundamentals and in-depth analysis of GenKyoTex
Our stock analysis for GenKyoTex stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GenKyoTex. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.